Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-10-25
2008-10-07
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07432249
ABSTRACT:
Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2′-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4373071 (1983-02-01), Itakura
patent: 4401796 (1983-08-01), Itakura
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4507433 (1985-03-01), Miller et al.
patent: 4720483 (1988-01-01), Jansz et al.
patent: 4757141 (1988-07-01), Fung et al.
patent: 4812512 (1989-03-01), Buendia et al.
patent: 4908405 (1990-03-01), Bayer et al.
patent: 5013830 (1991-05-01), Ohtsuka et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5082934 (1992-01-01), Saba et al.
patent: 5130302 (1992-07-01), Spielvogel
patent: 5142047 (1992-08-01), Tullis
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5177198 (1993-01-01), Spielvogel et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5235033 (1993-08-01), Summerton et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264562 (1993-11-01), Matteucci
patent: 5264564 (1993-11-01), Matteucci
patent: 5359044 (1994-10-01), Cook et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5391667 (1995-02-01), Dellinger
patent: 5403711 (1995-04-01), Walder et al.
patent: 5424413 (1995-06-01), Hogan et al.
patent: 5457191 (1995-10-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5484908 (1996-01-01), Froehler et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5506212 (1996-04-01), Hoke et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5506351 (1996-04-01), McGee
patent: 5508270 (1996-04-01), Baxter et al.
patent: 5514786 (1996-05-01), Cook et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5561043 (1996-10-01), Cantor et al.
patent: 5612469 (1997-03-01), Goodchild
patent: 5614617 (1997-03-01), Cook et al.
patent: 5631148 (1997-05-01), Urdea
patent: 5639873 (1997-06-01), Barascut et al.
patent: 5719271 (1998-02-01), Cook et al.
patent: 5760202 (1998-06-01), Cook et al.
patent: 5804683 (1998-09-01), Usman et al.
patent: 5861493 (1999-01-01), Cook et al.
patent: 5891683 (1999-04-01), Usman et al.
patent: 5891684 (1999-04-01), Usman et al.
patent: 5898031 (1999-04-01), Crooke et al.
patent: 5955443 (1999-09-01), Bennett et al.
patent: 5962425 (1999-10-01), Walder et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 6087484 (2000-07-01), Goodchild
patent: 6107094 (2000-08-01), Crooke
patent: 6133246 (2000-10-01), McKay et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 6222025 (2001-04-01), Cook et al.
patent: 6262036 (2001-07-01), Arnold, Jr. et al.
patent: 6274723 (2001-08-01), Nilsen
patent: 6506559 (2003-01-01), Fire et al.
patent: 6573072 (2003-06-01), Goodchild
patent: 6818759 (2004-11-01), Beigelman et al.
patent: 6849726 (2005-02-01), Usman et al.
patent: 7022828 (2006-04-01), McSwiggen
patent: 2002/0165189 (2002-11-01), Crooke
patent: 2003/0096286 (2003-05-01), Crooke
patent: 2003/0096287 (2003-05-01), Crooke
patent: 2003/0096784 (2003-05-01), Crooke
patent: 2003/0119777 (2003-06-01), Crooke
patent: 2003/0125241 (2003-07-01), Wissenbach et al.
patent: 2003/0139585 (2003-07-01), Uhlmann et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0206887 (2003-11-01), Morrissey et al.
patent: 2004/0029275 (2004-02-01), Brown et al.
patent: 2004/0146867 (2004-07-01), Slattum et al.
patent: 2005/0142535 (2005-06-01), Damha et al.
patent: 101 00 588 (2002-07-01), None
patent: 10100588 (2002-07-01), None
patent: 0 266 168 (1988-05-01), None
patent: 339842 (1989-11-01), None
patent: 2-264792 (1990-10-01), None
patent: WO92/07065 (1992-04-01), None
patent: WO92/20822 (1992-11-01), None
patent: WO92/20823 (1992-11-01), None
patent: WO92/22651 (1992-12-01), None
patent: WO 93/07883 (1993-04-01), None
patent: WO 9401550 (1994-01-01), None
patent: WO 94/02498 (1994-02-01), None
patent: WO94/02499 (1994-02-01), None
patent: WO94/02501 (1994-02-01), None
patent: WO94/17093 (1994-08-01), None
patent: WO 96/07392 (1996-03-01), None
patent: 9746570 (1997-12-01), None
patent: WO 97/46570 (1997-12-01), None
patent: 9932619 (1999-07-01), None
patent: 0063364 (2000-10-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 02/44321 (2002-06-01), None
patent: 2004097049 (2004-11-01), None
Struck, “Vaccine R&D Success Rates And Development Times,”Nature Biotechnology, May 1996, vol. 14, pp. 591-593.
Ohtsuka et al., “Recognition By Restriction EndonucleaseEcoRI Of Deoxyoctanucleotides Containing Modified Sugar Moieties,”J. Biochem, 1984, vol. 139, pp. 447-450.
International Search Report Dated Aug. 23, 2004 for International Application No. PCT/US03/09808.
Arya, S. K. et al., “Inhibition of RNA Directed DNA Polymerase of Murine Leukemia Virus by 2′-O-Alkylated Polyadenylic Acids,” Biochem. Biophys. Res. Commun. (1974) 59(2):608-615.
Arya, S. K. et al., “Inhibition of Synthesis of Murine Leukemia Virus in Cultured Cells by Polyribonucleotides and Their 2′-O-Alkyl Derivatives,” Mol. Pharm. (1976) 12:234-241.
De Clercq, E. et al., “Influence of Various 2- and 2′- Substituted Polyadenylic acids on Murine Leukemia Virus Reverse Transcriptase,” Cancer Lett. (1979) 7:27-37.
Hamilton, A. J. et al., “A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants,” Science (1999) 286:950-952.
Hobbs, J. et al., “Polynucleotides Containing 2′-Chloro-2′-deoxyribose,” Biochem. (1972) 11(23):4336-4344.
Hobbs, J. et al., “Poly 2′-Deoxy-2′-Aminouridylic Acid,” Biochem. Biophys. Res. Commun. (1972) 46(4):1509-1515.
Hobbs, J. et al., “Polynucleotides Containing 2′-Amino-2′-deoxyribose and 2′-Azido-2′-deoxyribose,” Biochem. (1973) 12(25):5138-5145.
Hunter, C. P., “Genetics: A touch of elegance with RNAi,” Current Biology (1999) 9:R440-R442.
Kumar, M. et al., “Antisense RNA: Function and Fate of Duplex RNA in Cells of Higher Eukaryotes,” Microbiol. Mol. Biol. Rev. (1998) 62(4):1415-1434.
Pieken, W. A. et al., “Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes,” Science (1991) 253:314-317.
Pilet, J. et al., “Structural Parameters of Single and Double Stranded Helical Polyribonucleotides,” Biochem. Biophys. Res. Commun. (1973) 52(2):517-523.
Rottman, F. et al., “Polynucleotides Containing 2′-O-Methyladenosine. I. Synthesis of Polynucleotide Phosphorylase,” Biochem. (1968) 7(7):2634-2641.
Rottman, F. et al., “Polymers Containing 2′-O-Methylnucleotides. II. Synthesis of Heteropolymers,” Biochem. (1969) 8(11):4354-4361.
Wincott, F. et al., “Synthesis, deprotection, analysis and purification of RNA and ribozymes,” Nucle
Isis Pharmaceuticals , Inc.
McGarry Sean R
Woodcock & Washburn LLP
LandOfFree
Oligoribonucleotides and ribonucleases for cleaving RNA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligoribonucleotides and ribonucleases for cleaving RNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligoribonucleotides and ribonucleases for cleaving RNA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013713